Regulatory Transparency: Forthcoming Lessons from the FDA

被引：0
|
作者：
Chakraborty, Sweta [1 ]
Lofstedt, Ragnar E. [1 ]
机构：
[1] Kings Coll London, London, England
来源：
EUROPEAN JOURNAL OF RISK REGULATION | 2010年 / 1卷 / 02期
关键词：
D O I：
10.1017/SI867299X00000271
中图分类号：
D9 [法律]; DF [法律];
学科分类号：
0301 ;
摘要：
引用
收藏
页码：159 / 162
页数：5
相关论文
共 50 条
  • [31] Navigating the FDA regulatory landscape
    Pamela D. Scott
    Anita Bajaj
    David P. McMullen
    Neuropsychopharmacology, 2024, 49 : 18 - 22
  • [32] Multimodal Analysis of FDA Drug Safety Communications: Lessons from Zolpidem
    Kesselheim, Aaron S.
    Sinha, Michael S.
    Campbell, Eric G.
    Schneeweiss, Sebastian
    Rausch, Paula
    Lappin, Brian M.
    Zhou, Esther H.
    Avorn, Jerry
    Dal Pan, Gerald J.
    DRUG SAFETY, 2019, 42 (11) : 1287 - 1295
  • [33] Multimodal Analysis of FDA Drug Safety Communications: Lessons from Zolpidem
    Aaron S. Kesselheim
    Michael S. Sinha
    Eric G. Campbell
    Sebastian Schneeweiss
    Paula Rausch
    Brian M. Lappin
    Esther H. Zhou
    Jerry Avorn
    Gerald J. Dal Pan
    Drug Safety, 2019, 42 : 1287 - 1295
  • [34] Lessons from FDA 483s and cGMP inspection data
    Pazhayatil, Ajay Babu
    Ingram, Marzena
    Sayeed, Naheed
    Pharmaceutical Technology, 2019, 43 (10) : 56 - 61
  • [35] Can we learn lessons from the FDA’s approval of aducanumab?
    Kathy Y. Liu
    Robert Howard
    Nature Reviews Neurology, 2021, 17 : 715 - 722
  • [36] Transparency and grand corruption: Lessons from the Colombia school meals program
    Keefer, Philip
    Roseth, Benjamin
    JOURNAL OF COMPARATIVE ECONOMICS, 2024, 52 (02) : 445 - 462
  • [37] The value-ladenness of transparency in science: Lessons from Lyme disease
    Elliott, Kevin C.
    STUDIES IN HISTORY AND PHILOSOPHY OF SCIENCE, 2021, 88 : 1 - 9
  • [38] Fairness, Accountability, Transparency in AI at Scale: Lessons from National Programs
    Ahmad, Muhammad Aurangzeb
    Teredesai, Ankur
    Eckert, Carly
    FAT* '20: PROCEEDINGS OF THE 2020 CONFERENCE ON FAIRNESS, ACCOUNTABILITY, AND TRANSPARENCY, 2020, : 690 - 690
  • [39] Can we learn lessons from the FDA's approval of aducanumab?
    Liu, Kathy Y.
    Howard, Robert
    NATURE REVIEWS NEUROLOGY, 2021, 17 (11) : 715 - 722
  • [40] Promoting transparency, accountability, and access through a multi-stakeholder initiative: Lessons from the medicines transparency alliance
    Vian T.
    Kohler J.C.
    Forte G.
    Dimancesco D.
    Journal of Pharmaceutical Policy and Practice, 10 (1)
12345